Kalaris Therapeutics (KLRS) Change in Account Payables (2024 - 2026)
Kalaris Therapeutics (KLRS) posted quarterly Change in Account Payables of -$376000.0 for Q1 2026, down 140.26% year-over-year from $934000.0 in Q1 2025, and down 143.02% quarter-over-quarter from $874000.0 in Q4 2025.
Kalaris Therapeutics (KLRS) Change in Account Payables (2024 - 2026) Analysis & Trends
Kalaris Therapeutics' Change in Account Payables history runs 3 years deep, the most recent figure standing at -$376000.0 for Q1 2026.
- In Q1 2026, Change in Account Payables fell 140.26% year-over-year to -$376000.0; the TTM figure through Mar 2026 stood at -$1.4 million (down 222.42% YoY), while the FY2025 annual figure was -$88000.0, up 91.43% from the prior year.
- Change in Account Payables for Q1 2026 stood at -$376000.0, down from $874000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $1.7 million in Q3 2024, with the low at -$3.2 million in Q3 2025.
- The 3-year median for Change in Account Payables is -$376000.0 (2026), against an average of -$165666.7.
- Peak annual rise in Change in Account Payables reached 318.76% in 2025, while the deepest fall reached 288.02% in 2025.
- Kalaris Therapeutics' Change in Account Payables stood at -$898000.0 in 2024, then soared by 197.33% to $874000.0 in 2025, then tumbled by 143.02% to -$376000.0 in 2026.
- Business Quant data shows KLRS's Change in Account Payables at -$376000.0 in Q1 2026, $874000.0 in Q4 2025, and -$3.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Kalaris Therapeutics | 100.19 Mn | 100.19 Mn | - | 144,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 144,000.00 |
| Jun 30, 2026 | 144,000.00 |
| Mar 31, 2026 | -376,000.00 |
| Mar 31, 2026 | -376,000.00 |
| Dec 31, 2025 | 874,000.00 |
| Dec 31, 2025 | 874,000.00 |
| Sep 30, 2025 | -3.20 Mn |
| Sep 30, 2025 | -3.20 Mn |
| Jun 30, 2025 | 1.31 Mn |
| Jun 30, 2025 | 1.31 Mn |
| Mar 31, 2025 | 934,000.00 |
| Mar 31, 2025 | 934,000.00 |
| Dec 31, 2024 | -898,000.00 |
| Dec 31, 2024 | -898,000.00 |
| Sep 30, 2024 | 1.70 Mn |
| Sep 30, 2024 | 1.70 Mn |
| Jun 30, 2024 | -597,000.00 |
| Jun 30, 2024 | -597,000.00 |
| Mar 31, 2024 | -1.24 Mn |
| Mar 31, 2024 | -1.24 Mn |